Location Directory

Clinical trials in Tampa, Florida

This page shows live ClinicalTrials.gov search results for Tampa, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 9:42 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

9123

Shown on this page

Current sort

Institutions in Tampa

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Moffitt Cancer Center

Live official records

Open in full search

Conditions: Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, TFE3-Rearranged Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma
Interventions: Axitinib, Nivolumab; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 266
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 168 more

Conditions: Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Interventions: Biopsy Procedure, Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 479
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 303 more

Conditions: Major Depressive Disorder
Interventions: Osavampator, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 24
States / cities: Oceanside, California • Orange, California • San Jose, California + 21 more

Conditions: Arterial Thromboembolism, Venous Thromboembolism, Pulmonary Embolism
Interventions: Prodigy Thrombectomy System, Symphony Thrombectomy System; Device
Lead sponsor: Imperative Care, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 13
States / cities: Huntsville, Alabama • Clearwater, Florida • Jacksonville, Florida + 10 more

Conditions: Severe Asthma
Interventions: GB-0895, Placebo; Drug
Lead sponsor: Generate Biomedicines; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 786 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 36
States / cities: Northridge, California • Pasadena, California • Rancho Cucamonga, California + 31 more

Conditions: Phenylketonuria
Interventions: JNT-517, JNT-517 Matching Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 10
States / cities: Los Angeles, California • Gainesville, Florida • Tampa, Florida + 7 more

Conditions: Polymyalgia Rheumatica
Interventions: Sarilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 47
States / cities: Avondale, Arizona • Phoenix, Arizona • Tucson, Arizona + 42 more

Conditions: Moderate-to-Severe Atopic Dermatitis
Interventions: Rezpegaldesleukin, Placebo; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 20
States / cities: Phoenix, Arizona • North Little Rock, Arkansas • Fountain Valley, California + 16 more

Conditions: Advanced Or Metastatic Merkel Cell Carcinoma
Interventions: IFx-Hu2.0, Pembrolizumab; Drug
Lead sponsor: TuHURA Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Tampa, Florida • Madison, Wisconsin

Conditions: Treatment Resistant Depression
Interventions: Vagus Nerve Stimulation (VNS); Device
Lead sponsor: LivaNova; Industry
Eligibility: 18 Years and older
Enrollment: 6,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 101
States / cities: Birmingham, Alabama • Huntsville, Alabama • Burlingame, California + 85 more

Conditions: Persistent Corneal Epithelial Defect
Interventions: TP-06, Vehicle of TP-06; Drug
Lead sponsor: Tarsus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 7 more

Conditions: Acute Myeloid Leukemias
Interventions: Revumenib, Placebo, Intensive Chemotherapy Regimen; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 11
States / cities: Goodyear, Arizona • Duarte, California • Farmington, Connecticut + 8 more

Clinical trials in Tampa, Florida

Filter and sort this location

Institutions in Tampa

Live official records

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Aspiration Thrombectomy Using the Symphony or Prodigy System

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

A Study of JNT-517 in Participants With Phenylketonuria (PKU)

Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

A Study to Evaluate the Efficacy and Safety of TP-06 for PCED

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation